New EMEA NSAID Study Could Put Teeth In EU Labeling Suggestion
This article was originally published in The Tan Sheet
Executive Summary
The European Medicines Agency is considering whether it should pursue mandatory NSAID labeling requirements across the European Union that would warn of increased risk of thrombotic events associated with use of products in the category
You may also be interested in...
Naproxen Fares Better Than Ibuprofen In Cardiovascular-Risk Data
Traditional non-selective NSAIDs, with the exception of naproxen, carry similar cardiovascular risk to COX-2 inhibitors, according to results of a study released by the Agency for Healthcare Research & Quality (AHRQ) Sept. 25
EMEA Calls For NSAID Labeling Consistency, Notes “No New Safety Concerns”
Labeling regarding established NSAID safety concerns should be made consistent across European Union member states, the European Medicines Agency said Oct. 17
Jurors' Answers In FTC Complaint Against Prevagen Might Form A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.